These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 25241913)

  • 1. An overview of the effects of anti-IgE therapies.
    Yalcin AD
    Med Sci Monit; 2014 Sep; 20():1691-9. PubMed ID: 25241913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of omalizumab on eosinophil cationic peptide, 25-hydroxyvitamin-D, IL-1β and sCD200 in cases of Samter's syndrome: 36 months follow-up.
    Yalcin AD; Uçar S; Gumuslu S; Strauss LG
    Immunopharmacol Immunotoxicol; 2013 Aug; 35(4):524-7. PubMed ID: 23841472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Omalizumab is effective in treating severe asthma in patients with severe cardiovascular complications and its effects on sCD200, d-dimer, CXCL8, 25-hydroxyvitamin D and IL-1β levels.
    Yalcin AD; Cilli A; Bisgin A; Strauss LG; Herth F
    Expert Opin Biol Ther; 2013 Sep; 13(9):1335-41. PubMed ID: 23883435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omalizumab beyond asthma.
    Sanchez J; Ramirez R; Diez S; Sus S; Echenique A; Olivares M; Cardona R
    Allergol Immunopathol (Madr); 2012; 40(5):306-15. PubMed ID: 22264640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Omalizumab in children.
    Licari A; Marseglia A; Caimmi S; Castagnoli R; Foiadelli T; Barberi S; Marseglia GL
    Paediatr Drugs; 2014 Dec; 16(6):491-502. PubMed ID: 25404353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal study of the expression of FcεRI and IgE on basophils and dendritic cells in association with basophil function in two patients with severe allergic asthma treated with Omalizumab.
    Pereira Santos MC; Campos Melo A; Caetano A; Caiado J; Mendes A; Pereira Barbosa M; Branco Ferreira M
    Eur Ann Allergy Clin Immunol; 2015 Mar; 47(2):38-40. PubMed ID: 25781192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-IgE monoclonal antibody (omalizumab) in the treatment of atopic asthma and allergic respiratory diseases.
    D'Amato G; Liccardi G; Noschese P; Salzillo A; D'Amato M; Cazzola M
    Curr Drug Targets Inflamm Allergy; 2004 Sep; 3(3):227-9. PubMed ID: 15379589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omalizumab in allergic diseases, a recent review.
    Vichyanond P
    Asian Pac J Allergy Immunol; 2011 Sep; 29(3):209-19. PubMed ID: 22053590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IgE-Related Chronic Diseases and Anti-IgE-Based Treatments.
    Navinés-Ferrer A; Serrano-Candelas E; Molina-Molina GJ; Martín M
    J Immunol Res; 2016; 2016():8163803. PubMed ID: 28097159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omalizumab: anti-IgE monoclonal antibody E25, E25, humanised anti-IgE MAb, IGE 025, monoclonal antibody E25, Olizumab, Xolair, rhuMAb-E25.
    BioDrugs; 2002; 16(5):380-6. PubMed ID: 12408744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Omalizumab. A review of the new treatment of allergic asthma and seasonal allergic rhinitis.
    Félix Toledo R; Negro Alvarez JM; Miralles López JC
    Allergol Immunopathol (Madr); 2002; 30(2):94-9. PubMed ID: 11958741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).
    Milgrom H; Berger W; Nayak A; Gupta N; Pollard S; McAlary M; Taylor AF; Rohane P
    Pediatrics; 2001 Aug; 108(2):E36. PubMed ID: 11483846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of human cord blood-derived mast cell responses by anti-Fc epsilon RI mAb 15/1 versus anti-IgE Omalizumab.
    Mirkina I; Schweighoffer T; Kricek F
    Immunol Lett; 2007 Apr; 109(2):120-8. PubMed ID: 17368811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-IgE therapy: clinical utility and mechanistic insights.
    Logsdon SL; Oettgen HC
    Curr Top Microbiol Immunol; 2015; 388():39-61. PubMed ID: 25553794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. D-dimer levels decreased in severe allergic asthma and chronic urticaria patients with the omalizumab treatment.
    Yalcin AD; Celik B; Gumuslu S
    Expert Opin Biol Ther; 2014 Mar; 14(3):283-6. PubMed ID: 24359555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced FcepsilonRI-mediated release of asthma-promoting cytokines and chemokines from human basophils during omalizumab therapy.
    Oliver JM; Tarleton CA; Gilmartin L; Archibeque T; Qualls CR; Diehl L; Wilson BS; Schuyler M
    Int Arch Allergy Immunol; 2010; 151(4):275-84. PubMed ID: 19844128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of action of anti-immunoglobulin E therapy.
    Soresi S; Togias A
    Allergy Asthma Proc; 2006; 27(2 Suppl 1):S15-23. PubMed ID: 16722327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Omalizumab, an anti-immunoglobulin E antibody: state of the art.
    Incorvaia C; Mauro M; Russello M; Formigoni C; Riario-Sforza GG; Ridolo E
    Drug Des Devel Ther; 2014; 8():197-207. PubMed ID: 24532966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-IgE--emerging opportunities for Omalizumab.
    Babu KS; Polosa R; Morjaria JB
    Expert Opin Biol Ther; 2013 May; 13(5):765-77. PubMed ID: 23517576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases.
    Chang TW; Wu PC; Hsu CL; Hung AF
    Adv Immunol; 2007; 93():63-119. PubMed ID: 17383539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.